CATEGORY: IMMUNE HEALTH
A rescue inhaler that carries an anti-inflammatory steroid alongside the usual airway opener cut severe asthma attacks by 47% in people with mild asthma, compared with the standard albuterol-only inhaler. In the year-long BATURA trial of 2,421 patients, 5.1% of those using the combination had a severe flare-up, versus 9.1% of those using albuterol alone.1
Clearing the Smoke Without Touching the Fire
Albuterol relaxes the muscle wrapped around the airways within minutes. It clears the smoke, so to speak, while doing nothing about the fire: the airway inflammation that builds underneath a flare and keeps feeding it. Budesonide is an inhaled corticosteroid that damps that inflammation directly. The logic of combining them is that the moment someone needs relief is exactly the moment their airways need the anti-inflammatory too. Each puff treats the cause along with the symptom.
Mild Asthma Was the Open Question
Anti-inflammatory rescue inhalers had already proved themselves at the severe end. The MANDALA trial showed in 2022 that this same albuterol-budesonide combination cut severe attacks by about a quarter in moderate-to-severe asthma.2 Mild asthma is where most people with the condition actually live, and a rescue inhaler is often the only medicine they carry. BATURA enrolled people 12 and older, nearly all of them adults, whose asthma was treated with nothing more than a rescue inhaler or a low-dose daily controller and still broke through. A random split handed half the combination and half plain albuterol, each used only as needed. Researchers then counted severe exacerbations: attacks bad enough to need steroid pills, an emergency visit or a hospital stay. The answer arrived early. A planned interim look found the gap so clear that the trial was stopped ahead of schedule.
What the Attack Rate Looked Like Up Close
Counted another way, the combination group averaged 0.15 severe attacks per person per year. The albuterol group averaged 0.32, roughly one severe attack for every three people each year. Mild asthma earns its name from the day-to-day symptoms, not from the flare-ups, which can turn dangerous at any level of the disease. That’s the stake here. These were people who mostly felt fine between episodes, and the inhaler they reached for on bad days changed how often a bad day became a hospital-grade one. Your obvious next question might be whether this replaces a daily controller inhaler. The trial can’t answer that. It compared two rescue inhalers, and people already on low-dose daily treatment stayed on it either way.
Less Steroid in Total, Not More
Worried about taking a steroid with every puff? The numbers ran the other way. People using the combination took in an average of 23 mg of systemic corticosteroid over the year. The albuterol-only group averaged 62 mg, most of it from the prednisone bursts that follow a severe attack. Small inhaled doses up front spared people much larger oral doses later. Side effects were comparable, with serious adverse events at 3.1% in both groups. As with many large drug trials, this one was funded by AstraZeneca, which markets the combination as Airsupra. The company also funded the earlier MANDALA trial, which found a similar pattern in more severe asthma.
Key Takeaways
- Among people with mild asthma, an as-needed albuterol-budesonide inhaler cut severe attacks nearly in half: 5.1% versus 9.1% of patients over about a year.
- Total steroid exposure fell by roughly two-thirds with the combination, because fewer severe attacks meant far fewer courses of steroid pills.
- The result extends to mild asthma what the MANDALA trial showed in moderate-to-severe disease; both trials were funded by the inhaler’s maker.